Table 1 Clinicopathologic features of 60 metaplastic breast carcinomas included in this study.
From: TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer
Predominant histologic component | ||||||
|---|---|---|---|---|---|---|
MBCs | SQUAMOUS | SPINDLE | OSSEOUS | CHONDROID | ||
(n = 60) | (n = 14) | (n = 16) | (n = 5) | (n = 25) | ||
Histologic gradea | 2 | 5 (8%) | 1 (7%) | 1 (6%) | 0 | 3 (12%) |
3 | 55 (92%) | 13 (93%) | 15 (94%) | 5 | 22 (88%) | |
Matrix producing | No | 32 (53%) | 14 (100%) | 16 (100%) | 1 (20%) | 1 (4%) |
Yes | 28 (47%) | 0 | 0 | 4 (80%) | 24 (96%) | |
ER status | Negative | 59 (98%) | 13 (93%) | 16 (100%) | 5 (100%) | 25 (100%) |
Positive | 0 | 0 | 0 | 0 | 0 | |
Not available | 1 (2%) | 1 (7%) | 0 | 0 | 0 | |
PR status | Negative | 59 (98%) | 13 (93%) | 16 (100%) | 5 (100%) | 25 (100%) |
Positive | 0 | 0 | 0 | 0 | 0 | |
Not available | 1 (2%) | 1 (7%) | 0 | 0 | 0 | |
HER2 status | Negative | 57 (95%) | 11 (79%) | 16 (100%) | 5 (100%) | 25 (100%) |
Positive | 2 (3%) | 2 (14%) | 0 | 0 | 0 | |
Not available | 1 (2%) | 1 (7%) | 0 | 0 | 0 | |
Triple-negative phenotype | n (%) | 57 (95%) | 11 (79%) | 16 (100%) | 5 (100%) | 25 (100%) |
